FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

Post-LOE

fexofenadine hydrochloride and pseudoephedrine hydrochloride

Aurobindo Pharma

ANDAORALTABLET, EXTENDED RELEASE

Approved

Apr 2025

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

2/8 — Basic

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE (fexofenadine hydrochloride and pseudoephedrine hydrochloride) by Aurobindo Pharma. Approved for these symptoms due to hay fever, other upper respiratory allergies: ▪ runny nose ▪ sneezing ▪ itchy, watery eyes ▪ itching of the nose and 4 more indications. First approved in 2025.

Drug data last refreshed 1w ago

Mechanism of Action

Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.

Indications (7)

these symptoms due to hay fever other upper respiratory allergies: ▪ runny nose ▪ sneezing ▪ itchy

Worked on FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.